Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1998 1
1999 1
2002 2
2003 1
2004 2
2005 1
2006 1
2007 3
2008 1
2010 1
2012 1
2013 1
2014 3
2015 2
2016 2
2017 3
2018 1
2019 3
2020 2
2021 2
2022 3
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
When and How to Combine Antiplatelet and Anticoagulant Drugs?
Espinola-Klein C. Espinola-Klein C. Hamostaseologie. 2022 Feb;42(1):73-79. doi: 10.1055/a-1724-4922. Epub 2022 Feb 23. Hamostaseologie. 2022. PMID: 35196733 Free article.
The most recent situations are a more intensive antithrombotic therapy for risk reduction in patients with atherosclerosis and temporary addition of antiplatelet drugs in patients with indication for long-term anticoagulation. Temporary combination of antiplatelet and anti …
The most recent situations are a more intensive antithrombotic therapy for risk reduction in patients with atherosclerosis and temporary add …
Oral rivaroxaban for symptomatic venous thromboembolism.
EINSTEIN Investigators; Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. EINSTEIN Investigators, et al. N Engl J Med. 2010 Dec 23;363(26):2499-510. doi: 10.1056/NEJMoa1007903. Epub 2010 Dec 3. N Engl J Med. 2010. PMID: 21128814 Free article. Clinical Trial.
CONCLUSIONS: Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation. ...
CONCLUSIONS: Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that ma …
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
EINSTEIN–PE Investigators; Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. EINSTEIN–PE Investigators, et al. N Engl J Med. 2012 Apr 5;366(14):1287-97. doi: 10.1056/NEJMoa1113572. Epub 2012 Mar 26. N Engl J Med. 2012. PMID: 22449293 Free article. Clinical Trial.
CONCLUSIONS: A fixed-dose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and long-term treatment of pulmonary embolism and had a potentially improved benefit-risk profile. ...
CONCLUSIONS: A fixed-dose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and long-term treatment of …
Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy.
Aboyans V, Bauersachs R, Mazzolai L, Brodmann M, Palomares JFR, Debus S, Collet JP, Drexel H, Espinola-Klein C, Lewis BS, Roffi M, Sibbing D, Sillesen H, Stabile E, Schlager O, De Carlo M. Aboyans V, et al. Among authors: espinola klein c. Eur Heart J. 2021 Oct 14;42(39):4013-4024. doi: 10.1093/eurheartj/ehab390. Eur Heart J. 2021. PMID: 34279602
In the absence of specific indications for chronic oral anticoagulation due to concomitant cardiovascular disease, a single antiplatelet agent is the basis for long-term antithrombotic treatment in patients with aortic or peripheral arterial diseases. ...
In the absence of specific indications for chronic oral anticoagulation due to concomitant cardiovascular disease, a single antiplatelet age …
[Antithrombotic therapy after peripheral revascularization].
Espinola-Klein C. Espinola-Klein C. Dtsch Med Wochenschr. 2021 Feb;146(3):136-140. doi: 10.1055/a-1129-1999. Epub 2021 Jan 29. Dtsch Med Wochenschr. 2021. PMID: 33513644 German.
In addition to antithrombotic medication risk factor management and regular follow-up examinations are important improve long-term prognosis after peripheral revascularization....
In addition to antithrombotic medication risk factor management and regular follow-up examinations are important improve long-term pr …
Health effects of e-cigarettes and their use for smoking cessation from a vascular perspective.
Krabbe B, Espinola-Klein C, Malyar N, Brodmann M, Mazzolai L, Belch JJF, Müller OJ, Heiss C; DGA-German Society of Angiology Board; ESVM-European Society of Vascular Medicine Board. Krabbe B, et al. Among authors: espinola klein c. Vasa. 2023 Mar;52(2):81-85. doi: 10.1024/0301-1526/a001056. Epub 2023 Feb 3. Vasa. 2023. PMID: 36734252 Free article.
But e-cigarettes are not risk-free and their use causes vascular damage. There is concern about long-term health risks of e-cigarettes or when non-smokers use them as first nicotine contact. ...
But e-cigarettes are not risk-free and their use causes vascular damage. There is concern about long-term health risks of e-cigarette …
Atherosclerosis and Its Impact on the Outcomes of Patients with Deep Venous Thrombosis.
Keller K, Prochaska JH, Coldewey M, Göbel S, Schmitt VH, Hahad O, Ullmann A, Nagler M, Lamparter H, Espinola-Klein C, Münzel T, Wild PS. Keller K, et al. Among authors: espinola klein c. Life (Basel). 2022 May 14;12(5):734. doi: 10.3390/life12050734. Life (Basel). 2022. PMID: 35629401 Free PMC article.
Symptomatic atherosclerosis was associated with increased mortality (HR 1.98 [95%CI 1.123.49], p = 0.018) and hospitalizations (HR 1.64 [95%CI 1.212.21], p = 0.0012) and primary long-term outcome (HR 1.99 [95%CI 1.313.04], p = 0.0013) during the 2 years follow-up-period in …
Symptomatic atherosclerosis was associated with increased mortality (HR 1.98 [95%CI 1.123.49], p = 0.018) and hospitalizations (HR 1.64 [95% …
Durability of open popliteal artery aneurysm repair.
Dorweiler B, Gemechu A, Doemland M, Neufang A, Espinola-Klein C, Vahl CF. Dorweiler B, et al. Among authors: espinola klein c. J Vasc Surg. 2014 Oct;60(4):951-7. doi: 10.1016/j.jvs.2014.04.035. Epub 2014 Jul 1. J Vasc Surg. 2014. PMID: 24993952 Free article.
OBJECTIVE: The objective of this study was to analyze our long-term results after open surgery for popliteal artery aneurysm. METHODS: Records of patients who received surgery between 1998 and 2010 were retrieved from a computerized database and analyzed retrospectively. . …
OBJECTIVE: The objective of this study was to analyze our long-term results after open surgery for popliteal artery aneurysm. METHODS …
Differential Inhibition of Platelet Reactivity by Dual Therapy With Aspirin and Low-Dose Rivaroxaban in Peripheral Arterial Disease: A Pilot Study.
Jurk K, Rothenaicher KF, Groß K, Rossmann H, Weißer G, Schmidtmann I, Münzel T, Espinola-Klein C. Jurk K, et al. Among authors: espinola klein c. Front Cardiovasc Med. 2022 May 6;9:865166. doi: 10.3389/fcvm.2022.865166. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35600474 Free PMC article.
In this pilot study, the platelet activation status in vivo and platelet reactivity in vitro were longitudinally analyzed by flow cytometric assays and calibrated automated thrombography in platelet-rich plasma (PRP) from 10 patients with PAD receiving ASA (100 mg, one time per d …
In this pilot study, the platelet activation status in vivo and platelet reactivity in vitro were longitudinally analyzed by flow cytometric …
Specialized Management of Oral Anticoagulation Therapy Improves Outcome in Patients with Chronic Renal Insufficiency.
Lauterbach M, Uhrich E, Eggebrecht L, Göbel S, Panova-Noeva M, Nagler M, Ten Cate V, Bickel C, Espinola-Klein C, Münzel T, Wild PS, Prochaska JH. Lauterbach M, et al. Among authors: espinola klein c. J Clin Med. 2020 Feb 28;9(3):645. doi: 10.3390/jcm9030645. J Clin Med. 2020. PMID: 32121153 Free PMC article.
The fluctuations in the international normalized ratios were significantly lower in CS-managed patients, and regardless of treatment in usual care or a CS, the time in therapeutic range was significantly lower in RF patients. Cox regression-adjusted hazard ratios for long-term …
The fluctuations in the international normalized ratios were significantly lower in CS-managed patients, and regardless of treatment in usua …
35 results